Supplemental material
Journal of Medical Economics
Volume 25, 2022 - Issue 1
Oncology
Long-term hospital resource utilization and associated costs of care for patients initiating nivolumab in advanced non-small cell lung cancer in France
Valentine Grumberga Bristol Myers Squibb France, Rueil-Malmaison, France;b Oncostat, CESP, INSERM U1018, Paris-Saclay University, “Ligue Contre le Cancer” labeled team, Villejuif, FranceCorrespondence[email protected]
https://orcid.org/0000-0002-2424-6748
https://orcid.org/0000-0002-2424-6748, Christos Chouaïdc Department of Chest Medicine, Créteil University Hospital, Créteil, France;d INSERM U955, UPEC, IMRB, Créteil, Francehttps://orcid.org/0000-0002-4290-5524
https://orcid.org/0000-0002-4290-5524, François-Emery Cottéa Bristol Myers Squibb France, Rueil-Malmaison, Francehttps://orcid.org/0000-0002-6758-4552
https://orcid.org/0000-0002-6758-4552, Baptiste Jouanetone HEVA, Lyon, Francehttps://orcid.org/0000-0001-6764-4335
https://orcid.org/0000-0001-6764-4335, Ronan Jolivele HEVA, Lyon, Francehttps://orcid.org/0000-0001-6389-5372
https://orcid.org/0000-0001-6389-5372, Anne-Françoise Gaudina Bristol Myers Squibb France, Rueil-Malmaison, Francehttps://orcid.org/0000-0002-6946-2479
https://orcid.org/0000-0002-6946-2479, Dorothée Reynauda Bristol Myers Squibb France, Rueil-Malmaison, Francehttps://orcid.org/0000-0003-0534-5713
https://orcid.org/0000-0003-0534-5713, Jean-Baptiste Assiéc Department of Chest Medicine, Créteil University Hospital, Créteil, France;f INSERM U1138 Centre de Recherche des Cordeliers (CRC), Paris, Francehttps://orcid.org/0000-0002-9749-4937
https://orcid.org/0000-0002-9749-4937 & Isabelle Borgetb Oncostat, CESP, INSERM U1018, Paris-Saclay University, “Ligue Contre le Cancer” labeled team, Villejuif, France;g Biostatistics and Epidemiology Office, Direction of Clinical Research, Gustave Roussy, Paris-Saclay University, Villejuif, Francehttps://orcid.org/0000-0002-6295-6361
https://orcid.org/0000-0002-6295-6361 show allRelated Research Data
Long-term hospital resource utilization and associated costs of care for patients initiating nivolumab in advanced non-small cell lung cancer in FranceDeclarations of financial/other interest
Source:
Taylor & Francis
Linking provided by
